BE1016292A3 - Verbinding en gebruik bij behandeling. - Google Patents

Verbinding en gebruik bij behandeling. Download PDF

Info

Publication number
BE1016292A3
BE1016292A3 BE2004/0472A BE200400472A BE1016292A3 BE 1016292 A3 BE1016292 A3 BE 1016292A3 BE 2004/0472 A BE2004/0472 A BE 2004/0472A BE 200400472 A BE200400472 A BE 200400472A BE 1016292 A3 BE1016292 A3 BE 1016292A3
Authority
BE
Belgium
Prior art keywords
treatment
connection
pharmaceutically acceptable
epicholecalciferol
bishomo
Prior art date
Application number
BE2004/0472A
Other languages
English (en)
Dutch (nl)
Inventor
Luciano Adorini
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Application granted granted Critical
Publication of BE1016292A3 publication Critical patent/BE1016292A3/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BE2004/0472A 2003-09-24 2004-09-24 Verbinding en gebruik bij behandeling. BE1016292A3 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (1)

Publication Number Publication Date
BE1016292A3 true BE1016292A3 (nl) 2006-07-04

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2004/0472A BE1016292A3 (nl) 2003-09-24 2004-09-24 Verbinding en gebruik bij behandeling.

Country Status (12)

Country Link
EP (1) EP1673096A1 (fr)
JP (2) JP2007506699A (fr)
CN (1) CN100488511C (fr)
BE (1) BE1016292A3 (fr)
BR (1) BRPI0404050A (fr)
CH (1) CH698144B1 (fr)
EA (1) EA010240B1 (fr)
FR (1) FR2859910B1 (fr)
HK (1) HK1085373A1 (fr)
NL (1) NL1027109C2 (fr)
NZ (1) NZ535531A (fr)
WO (1) WO2005027923A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038611A1 (fr) * 2004-10-05 2006-04-13 Kissei Pharmaceutical Co., Ltd. Agent pour le traitement prophylactique ou thérapeutique des troubles de collecte de l'urine dans la vessie consécutifs à l'obstruction du canal urinaire inférieur
JPWO2006038619A1 (ja) * 2004-10-06 2008-05-15 キッセイ薬品工業株式会社 前立腺肥大症に対する手術療法への移行予防用医薬組成物
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (fr) * 2017-03-20 2018-09-21 Pierre Fabre Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (fr) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Analogues de la vitamine D3
WO1998029123A1 (fr) * 1996-12-30 1998-07-09 Bone Care International, Inc. Procede de traitement de maladies prostatiques au moyen d'analogues actifs de la vitamine d
WO2003034961A1 (fr) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Procedes et dispositif transdermique de terazosine
WO2003047595A1 (fr) * 2001-12-03 2003-06-12 Novacea, Inc. Compositions pharmaceutiques comprenant des composes actifs de vitamine d

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
EP0981523B1 (fr) * 1997-05-16 2005-12-07 Woman & Infants Hospital Composes de vitamine d3 a ether cyclique et composes de 1alpha(oh)3-epi-vitamine d3, et utilisation desdits composes
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808833A2 (fr) * 1996-05-23 1997-11-26 F. Hoffmann-La Roche Ag Analogues de la vitamine D3
WO1998029123A1 (fr) * 1996-12-30 1998-07-09 Bone Care International, Inc. Procede de traitement de maladies prostatiques au moyen d'analogues actifs de la vitamine d
WO2003034961A1 (fr) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Procedes et dispositif transdermique de terazosine
WO2003047595A1 (fr) * 2001-12-03 2003-06-12 Novacea, Inc. Compositions pharmaceutiques comprenant des composes actifs de vitamine d

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANON: "BioXell commences phase II trial of BXL - 628", DRUG NEWS & PERSPECTIVES, (MAR 2003) VOL. 16, NO. 2, PP. 122-122. PUBLISHER: PROUS SCIENCE, SA, PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN. ISSN: 0214-0934., March 2003 (2003-03-01), XP001205124 *
BRANDL MICHAEL ET AL: "Chemical reactivity of Ro-26-9228, 1alpha-fluoro-25-hydroxy-16,23E-di ene-26,27-bishomo-20-epi-cholecalciferol in aqueous solution.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 92, no. 10, October 2003 (2003-10-01), pages 1981 - 1989, XP002315528, ISSN: 0022-3549 *
CRESCIOLI C ET AL: "Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 150, no. 4, April 2004 (2004-04-01), pages 591 - 603, XP009043025, ISSN: 0804-4643 *
http://www3.interscience.wiley.com/cgi-bin/abstract/104550629/ABSTRACT, Published Online 30 Jul 2003 *
MEALY N E: "BXL-628", DRUGS OF THE FUTURE 2004 SPAIN, vol. 29, no. 6, 2004, pages 629, XP009043214, ISSN: 0377-8282 *

Also Published As

Publication number Publication date
EA010240B1 (ru) 2008-06-30
WO2005027923A1 (fr) 2005-03-31
NZ535531A (en) 2006-03-31
JP2009035559A (ja) 2009-02-19
EA200401100A1 (ru) 2005-04-28
CH698144B1 (fr) 2009-05-29
NL1027109A1 (nl) 2005-03-29
HK1085373A1 (en) 2006-08-25
NL1027109C2 (nl) 2005-05-03
FR2859910B1 (fr) 2006-04-28
EP1673096A1 (fr) 2006-06-28
JP2007506699A (ja) 2007-03-22
BRPI0404050A (pt) 2005-06-14
CN100488511C (zh) 2009-05-20
CN1615891A (zh) 2005-05-18
FR2859910A1 (fr) 2005-03-25

Similar Documents

Publication Publication Date Title
HUP0100586A2 (hu) Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények
CL2007002953A1 (es) Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
LU93321I2 (fr) Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci
WO2008046083A3 (fr) Utilisation de composés oxindole comme agents thérapeutiques
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
WO2006015263A3 (fr) Analogues de lonidamine
WO2005074598A3 (fr) Composes precurseurs de nitroxyle et methodes d'utilisation
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
WO2007149406A8 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
TW200505434A (en) Therapeutic treatment
IL180979A (en) Isoindulin compounds and their use
MXPA04006731A (es) Sistema de administracion de farmacos que comprenden rapamicina y derivados de la misma para la prevencion y tratamiento de enfermedades vasculares.
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2003011117A3 (fr) Techniques et compositions destinees au traitement et a la prevention de lesions de la partie distale de l'intestin
WO2004064735A3 (fr) Traitement de l'hypertrophie prostatique benigne
HK1085373A1 (en) Compound and use in the manufacture of a medicament for the treatment of benign prostatic hyperplasia and associated symptoms
EA200970353A1 (ru) Комбинированное лекарственное средство
RS54185B1 (en) USE OF 24-ORDER
MX2009003743A (es) Uso de ciclosporinas modificadas.
PL1713438T3 (pl) Mydło lecznicze
NL1025844A1 (nl) Benzopyranverbindingen voor gebruik bij de behandeling en preventie van ontstekingsgerelateerde aandoeningen.
GB201115757D0 (en) Formulation for the treatment of benign prostate hyperplasia
NO20030985D0 (no) Behandling av betennelsestilstander

Legal Events

Date Code Title Description
RE Patent lapsed

Effective date: 20100930